GlassScriptPhysician profile
Deborah Pease
NPI 1487667606
$6,362.79
in general payments reported to CMS, 2019-2025
46 companies · $1,176 in 2025
The $1,176 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,403 · 2022: $1,839 · 2023: $1,019 · 2024: $927 · 2025: $1,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,121.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $912.57 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $790.50 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $729.55 | 2021-2025 | |
| Glaxosmithkline, LLC. | $600.67 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $289.69 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Medtronic, INC. | $229.55 | 2022-2025 | Inceptiv, Minimed 780g |
| Pfizer INC. | $223.83 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.03 | 2021-2025 | Jardiance |
| Amgen INC. | $205.07 | 2021-2025 | Otezla, Repatha, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.16 | 2021-2023 | Trulance, Xifaxan |
| Abbott Laboratories | $147.42 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $141.65 | 2022-2024 | |
| Lundbeck LLC | $131.73 | 2022-2025 | Vyepti, Rexulti |
| Janssen Pharmaceuticals, INC | $116.42 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $114.05 | 2021-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Pease listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.